ICH-IMAGE
Research type
Research Study
Full title
IntraCerebral Haemorrhage: Imaging Microglial Activation and blood-brain barrier leakaGE (ICH-IMAGE)
IRAS ID
181847
Contact name
Adrian Parry-Jones
Contact email
Sponsor organisation
The University of Manchester
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
We are interested in developing a new treatment for patients with a stroke caused by bleeding in to the brain (intracerebral haemorrhage). In the hours to days after bleeding occurs, we know that inflammation occurs in the brain around the blood clot. Although inflammation is the body's natural response to injury, when it continues unchecked it can worsen damage. We know that it does worsen damage after an intracerebral haemorrhage and we want to investigate whether blocking inflammation can improve outcomes.
Between the blood and brain, there is a highly specialised 'blood-brain barrier'. This is formed by the cells lining brain blood vessels as well as tissue and cells within the brain itself. How much of a drug can get to where it needs to act in the brain is largely governed by how well it can cross the blood-brain barrier. This makes the blood-brain barrier very important in drug development, as drugs to block brain inflammation have to cross it to get to where they need to go.
However, when the brain is damaged, the blood-brain barrier can become leaky. We know very little about this after intracerebral haemorrhage. This study (called IMAGE-ICH) will determine how leaky the blood-brain barrier is in the first three days after intracerebral haemorrhage. Forty intracerebral haemorrhage patients will undergo an MRI scan to measure leakiness in the first 3 days after their stroke. Twenty of these patients will go on to have a PET scan to show brain inflammation 2-7 days after their stroke. By putting the two scans together, we will be able to estimate how much of an anti-inflammatory drug will get to inflamed areas in the brain. This will help us to know how much of the drug to give and when to give it in subsequent clinical trials.
REC name
North West - Haydock Research Ethics Committee
REC reference
15/NW/0677
Date of REC Opinion
20 Oct 2015
REC opinion
Further Information Favourable Opinion